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ABSTRACT
Objectives: To assess contemporary data on
characteristics, management and 1-year postdischarge
outcomes in Iranian patients hospitalised with acute
coronary syndrome (ACS).
Setting: 11 tertiary care hospitals in 5 major cities in
the Islamic Republic of Iran.
Participants: Patients aged ≥20 and ≤80 years
discharged alive with confirmed diagnosis of ACS
including ST-segment elevation myocardial infarction
(STEMI), non-STEMI (NSTEMI) and high-risk unstable
angina (HR-UA).
Primary and secondary outcome measures:
Patients were followed up regarding the use of
medications and the end points of the study at
1 month and 1 year after discharge. The primary end
point of the study was 1-year postdischarge major
adverse cardiac and cerebrovascular events (MACCEs),
defined as mortality (cardiac and non-cardiac), ACS
and cerebrovascular attack (stroke and/or transient
ischaemic attack). The secondary end points were
hospital admission because of congestive heart failure,
revascularisation by coronary artery bypass grafting
surgery or percutaneous coronary intervention (PCI),
and major and minor bleeds.
Results: A total of 1799 patients (25.7% STEMI and
74.3% HR-UA/NSTEMI) discharged alive with
confirmed diagnosis of ACS were included in the final
analysis. During hospitalisation, the majority of the
patients received aspirin (98.6%), clopidogrel (91.8%),
anticoagulants (93.4%), statins (94.3%) and β-blockers
(89.3%). Reperfusion therapy was performed in 62.6%
of patients with STEMI (46.3% thrombolytic therapy
and 17.3% primary PCI). The mean door-to-balloon
and door-to-needle times were 82.9 and 45.6 min,
respectively. In our study, 64.7% and 79.5% of the
patients in HR-UA/NSTEMI and STEMI groups,
respectively, underwent coronary angiography. During
the 12 months after discharge, MACCEs occurred in
15.0% of all patients.
Conclusions: Our study showed that the composition
of Iranian patients with ACS regarding the type of ACS
is similar to that in developed European countries and
is unlike that in developing countries of the Middle
East and Africa. We found that our patients with ACS
are treated with high levels of adherence to guideline-
recommended in-hospital medications.
INTRODUCTION
Acute coronary syndrome (ACS) represents a
major healthcare burden worldwide. The
diagnosis and management of unstable
angina (UA), non-ST-segment elevation myo-
cardial infarction (NSTEMI) and STEMI
have been rapidly evolving in recent years.1
However, ACS continues to be a significant
health problem throughout the world, being
responsible for a substantial number of
Strengths and limitations of this study
▪ This is the first and only study on management
and outcomes of patients with acute coronary
syndrome (ACS) in Iran.
▪ In addition to assessment of in-hospital manage-
ment, the patients were followed up for 1 year
regarding the cardiovascular events and adher-
ence to evidence-based treatment for ACS.
▪ We comprehensively compared the situation of
Iran regarding management and outcome of ACS
with that in developed countries and developing
nations of the Middle East region.
▪ Although the study was multicentre and 11 hos-
pitals participated, it was not a population-based
registry and selection bias could have occurred.
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deaths due to cardiovascular diseases (CVDs). The status
of Middle Eastern nations in this context is especially
worrying, as, according to prediction by the WHO, they
will face the greatest increment in the absolute burden
of CVD in the world.2
In recent years, well-regarded scientific societies in
Europe and the USA have developed several guidelines
to improve the outcomes of ACS through implementa-
tion of recommendations into clinical practice.3–6 Most
of the real-world evidence about patients with ACS
comes from several large registries7–12 with data on dem-
ography, treatments and outcomes of patients in
middle-income and high-income countries, and little is
known about patients with ACS in developing countries.
Moreover, findings of the surveys and registries per-
formed so far demonstrate that epidemiology and man-
agement of patients with ACS differ a lot between
countries, and there is a wide gap between guidelines
and current clinical practice.1 7 13 14 Additionally, multi-
national registries often represent statistical averages for
the participating centres rather than representing a real,
existing geographical population.14 Hence, more repre-
sentative local registries are needed in developing coun-
tries to increase awareness of CVD burden, its
management and outcomes, in order to establish appro-
priate preventive and management strategies.
There are very limited data regarding the epidemi-
ology, management and outcomes of ACS in Iranian
patients. The Iranian Project for Assessment of Coronary
Events 2 (IPACE2) was a prospective nationwide multi-
centre registry designed to gain insights into the epi-
demiology, clinical characteristics, management and
1-year postdischarge outcomes of Iranian patients hospi-
talised with ACS.
MATERIALS AND METHODS
Study participants
Between April 2011 and November 2012, we established
a prospective multicentre registry that recruited patients
aged ≥20 and ≤80 years with any type of ACS (STEMI,
NSTEMI or high risk (HR)-UA) from 11 hospitals in five
major cities in the Islamic Republic of Iran.
We obtained ethical approval before initiation of the
study and all patients provided informed consent.
According to the protocol, all admitted patients with
suspected ACS were screened to be eligible to enter the
registry. However, we enrolled those patients with final
diagnosis of ACS who were discharged alive from hos-
pital and who gave informed consent for participation in
the study. The final diagnosis was made by the attending
cardiologist, based on clinical presentation, initial ECG
pattern and markers of myocardial necrosis acquired at
least 6 h after the symptom onset. The patients were
then classified as having HR-UA, NSTEMI or STEMI.
The definition of the final diagnosis was as follows:
▸ STEMI: presence of (1) ST-segment elevation consist-
ent with myocardial infarction (MI) of ≥2 mm in
adjacent chest leads and/or ST-segment elevation of
≥1 mm in two or more standard leads or new left
bundle branch block (LBBB) and (2) positive cardiac
necrosis markers.
▸ NSTEMI: (1) absence of ST-segment elevation con-
sistent with MI of ≥2 mm in adjacent chest leads and
ST-segment elevation of ≥1 mm in two or more stand-
ard leads and new LBBB and (2) positive cardiac
necrosis markers.
▸ HR-UA: (1) absence of ST-segment elevation consist-
ent with MI of ≥2 mm in adjacent chest leads and
ST-segment elevation of ≥1 mm in two or more stand-
ard leads and new LBBB and (2) negative cardiac
necrosis markers and (3) angina pectoris (or equiva-
lent type of ischaemic discomfort) with any one of
the three following features: (1) angina occurring at
rest and prolonged, >20 min, (2) new-onset angina of
at least Canadian Cardiovascular Society (CCS) class
III severity or (3) recent acceleration of angina
reflected by an increase in severity of at least one
CCS class to at least CCS class III.
Study protocol
A detailed protocol was prepared with inclusion and
exclusion criteria, methods and logistics, and definitions
of all fields in the registry dataset. Also, the representa-
tive investigators from each collaborating hospital
reviewed the workflow of the protocol in steering com-
mittee meetings before the registry was started. The
patient with ACS registry was designed to collect data on
demographic characteristics, medical history, cardiovas-
cular risk factors, clinical presentation, time of symptom
onset, early in-hospital management, reperfusion treat-
ment, time of admission and start of thrombolysis or
balloon, findings of diagnostic tests, hospital length of
stay, discharge medications, and 1-month and 1-year
follow-up for medications and outcomes.
Data for this registry were gathered at each centre by
investigators instructed on the use of standardised elec-
tronic case report forms (e-CRF). All investigators had a
username and password specific for them and were
trained on how to extract and enter data to the elec-
tronic web-based registry. During the data collection,
trained clinical audits supervised the compliance with
study protocol and validity of the data. Moreover, the
consistency and accuracy of data entry was overseen by a
qualified independent assessor.
Patients were followed up regarding the use of medica-
tions through phone calls or direct visits at 1 month and
1 year after discharge as well as at the end points of the
study. For the telephone follow-up interviews, at least
five attempts were made to contact participants or their
first-degree relatives. If telephone interviews were unsuc-
cessful, the participants were contacted by mail using
their home address. The primary endpoint of this study
was 1-year postdischarge major adverse cardiac and cere-
brovascular events (MACCEs), defined as mortality
(cardiac and non-cardiac), ACS and cerebrovascular
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attack (CVA) (stroke and/or transient ischaemic attack,
TIA). The secondary end points were hospital admission
because of congestive heart failure, revascularisation by
coronary artery bypass grafting (CABG) surgery or per-
cutaneous coronary intervention (PCI), and major and
minor bleeds. ACS was identified as HR-UA, NSTEMI or
STEMI, using the aforementioned definitions, that
resulted in readmission of the patient after discharge.
CVA (stroke and/or TIA) was defined as an acute neuro-
logical deficit accompanied by brain imaging compatible
with a recent ischaemic or haemorrhagic event. Major
bleeding was defined as overt clinical bleeding: (1) that
was associated with a drop in haemoglobin of more than
5 g/dL or a haematocrit of >15% (absolute); (2) that
caused haemodynamic compromise or (3) that required
a blood transfusion.
Adherence to guideline-recommended antiplatelet
treatment was defined based on the recommendations
of the “2011 American College of Cardiology (ACC)/
American Heart Association (AHA) Focused Update
of the Guidelines for the Management of Patients
With Unstable Angina/Non-ST-Elevation Myocardial
Infarction”3 and “2009 Focused Updates of ACC/AHA
Guidelines for the Management of Patients With
ST-Elevation Myocardial Infarction,”4 for antiplatelet
treatment on admission and after discharge in any sub-
group of patients with ACS. Full adherence was defined
as receiving antiplatelet treatment in compliance with
the guideline at all time points (at discharge, 1 month
after discharge and 1 year after discharge).
Role of the funding source
Sanofi-Aventis Groupe Iran Affiliate was the sponsor for
this study. The sponsor had significant contribution in
study design and preparation of the logistics. However, it
had no role in data analysis, data interpretation or
writing of the report. The Steering Committee, which
was composed of investigators and an agent of the
sponsor, was involved in the preparation and approval of
the protocol, and supervised the conduct of study. The
committee had full access to all the data in the study
and was given full authority for presentation and publi-
cation of the results.
Statistical analysis
The Kolmogorov-Smirnov test was applied to examine
normal distribution. The continuous variables are
expressed as mean±SD and were compared between the
STEMI/new LBBB and HR-UA/NSTEMI groups, using
the Student t test. The categorical variables were com-
pared using a χ2 test or the Fisher exact test, as appropri-
ate, and they are presented as absolute frequencies with
percentages. Multiple logistic regression analyses were
used to determine independent predictors of MACCEs
in patients with STEMI/new LBBB and also in patients
with HR-UA/NSTEMI at 1 year after discharge. Variables
were entered into the logistic regression model based on
their statistical significance in univariable analyses
(entering the criterion p≤0.1) as well as on their clinical
significance (based on the investigators’ discretion). The
final included variables in the model were heart rate on
admission, positive histories of diabetes mellitus (DM),
and/or peripheral arterial disease, PCI or CABG during
the admission or 1-year postdischarge, congestive heart
failure during admission or 1-year postdischarge, left
ventricular ejection fraction (LVEF)<40%, left main
disease or multivessel coronary artery disease in coron-
ary angiography and full adherence to guideline-recom-
mended antiplatelet therapy throughout the first year
after ACS. Moreover, we also included sex, typical chest
pain at presentation, history of CVA, reperfusion therapy
and anterior STEMI in the STEMI/new LBBB group.
For all analyses, the statistical package SPSS V.16.0 for
Windows (SPSS Inc, Chicago, Illinois, USA) was used.
All p values were two-tailed with significance defined as
p≤0.05.
RESULTS
Study population
Between April 2011 and November 2012, 1997 patients
with suspected ACS were recruited from 20 teaching hos-
pitals in five major cities of Iran. Of the 1997 patients
recruited, 1799 patients were discharged alive with con-
firmed diagnosis of ACS: 855 from Tehran (47.5%); 377
from Mashhad (21.0%); 167 from Tabriz (9.3%); 206
from Isfahan (11.5%) and 194 from Shiraz (10.8%).
One year follow-up was successfully completed in 1640
patients, for an overall follow-up rate of 91.2%.
Discharge diagnoses were STEMI/new LBBB in 463
patients (25.7%) and HR-UA/NSTEMI in 1336 patients
(74.3%). Of the patients with UA/NSTEMI, 377
(20.9%) had NSTEMI and 959 (53.3%) had HR-UA.
Table 1 shows the baseline demographic and clinical
characteristics of these groups. For the entire patient
group, the mean (±SD) age was 60.1 (±11.2) years and
65.4% were male. Patients with HR-UA/NSTEMI tended
to have more concomitant diseases including hyperten-
sion, hyperlipidaemia, DM and histories of UA, MI, PCI,
CABG and peripheral arterial disease than did patients
with STEMI/new LBBB. However, patients with STEMI/
new LBBB were more likely to be men, younger and
current smokers, and to present with typical ischaemic
chest pain.
In-hospital medications and interventions
Table 2 shows the prescription of guideline-recom-
mended medications in the first 24 h of admission in
the entire patient group. Aspirin and clopidogrel were
given to 98.6% and 91.8%, respectively, and 91.2% of
the patients received dual antiplatelet therapy (DAPT).
Patients with STEMI/new LBBB were more likely to
receive clopidogrel as well as DAPT than were patients
with HR-UA/NSTEMI. Overall, 94.3% of the patients
were treated with statins and 89.3% received β-blockers.
ACE inhibitors or angiotensin receptor blockers were
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administered in 81.9% of all patients, and 93.4%
received anticoagulation therapy with almost similar pro-
portions of intravenous unfractionated heparin and sub-
cutaneous low-molecular-weight heparin.
Among patients with STEMI/new LBBB, 290
(62.6%) underwent reperfusion therapy; 46.3% of the
patients with STEMI/new LBBB received thrombolytic
therapy, which was mostly streptokinase (table 3), and
primary PCI was carried out in 17.3% of the patients
with STEMI/new LBBB. The mean door-to-balloon
and door-to-needle times were 82.9 and 45.6 min,
respectively. Iranian patients with ACS had a mean
265.6 min delay from symptom onset to presenting to a
hospital.
Table 1 Baseline demographic and clinical characteristics of the study patients
Characteristics Total (n=1799) STEMI/new LBBB (n=463) UA/NSTEMI (n=1336) p Value
Demographics
Age, year 60.1±11.2 58.8±11.3 60.5±11.1 0.004
Male sex, n (%) 1177 (65.4) 371 (80.1) 806 (60.3) <0.0001
Presenting characteristics
Ischaemic-type chest pain, n (%) 1638 (91.1) 445 (96.1) 1193 (89.3) <0.0001
Cardiac arrest/ASCD, n (%) 2 (0.1) 2 (0.4) 0 (0.0) 0.066
Heart rate, bpm 78.6±17.3 78.7±16.6 78.5±17.6 0.829
SBP, mm Hg 135.4±25.6 133.9±26.7 135.9±25.2 0.140
DBP, mm Hg 82.2±15.0 82.6±16.2 82.1±14.6 0.585
Risk factors, n (%)
Hypertension 898 (49.9) 183 (39.5) 715 (53.6) <0.0001
Hyperlipidaemia 826 (45.9) 159 (34.9) 667 (50.5) <0.0001
Diabetes mellitus 559 (31.1) 120 (25.9) 439 (32.9) <0.0001
Family history of CAD 510 (28.4) 119 (27.4) 391 (31.0) 0.150
Smoking
Current 530 (29.5) 199 (43.0) 331 (24.8) <0.0001
Past 184 (10.2) 41 (8.9) 143 (10.7)
Medical history, n (%)
UA 797 (44.3) 119 (26.0) 678 (51.4) <0.0001
MI 330 (18.3) 60 (13.1) 270 (20.6) <0.0001
PCI 196 (10.9) 31 (6.7) 165 (12.4) 0.001
CABG 158 (8.8) 14 (3.0) 144 (10.8) <0.0001
CVA 93 (5.2) 20 (4.3) 73 (5.5) 0.324
PAD 30 (1.7) 3 (0.7) 27 (2.3) 0.034
All plus-minus values are mean±SD.
ASCD, aborted sudden cardiac death; CABG, coronary artery bypass grafting surgery; CAD, coronary artery disease; CVA, cerebrovascular
attack; DBP, diastolic blood pressure; LBBB, left bundle branch block; MI, myocardial infarction; NSTEMI, non-ST-segment elevation
myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI,
ST-segment elevation myocardial infarction; UA, unstable angina.
Table 2 In-hospital medication administered for the study patients
Characteristics Total (n=1799) STEMI/new LBBB (n=463) UA/NSTEMI (n=1336) p Value
Medications, n (%)
Aspirin 1773 (98.6) 460 (99.4) 1313 (98.3) 0.095
Clopidogrel 1652 (91.8) 454 (98.1) 1198 (89.7) <0.0001
Other antiplatelets 15 (0.8) 6 (1.3) 9 (0.7) 0.235
Dual antiplatelet therapy 1640 (91.2) 452 (97.6) 1188 (88.9) <0.0001
UFH 864 (48.0) 230 (49.7) 634 (47.5) 0.410
LMWH 817 (45.4) 197 (42.5) 620 (46.4) 0.151
Statin 1697 (94.3) 441 (95.2) 1256 (94.0) 0.322
β-blocker 1606 (89.3) 421 (90.9) 1185 (88.7) 0.181
ACEI/ARB 1473 (81.9) 403 (87.0) 1070 (80.1) 0.001
Nitrates 1653 (91.9) 417 (90.1) 1236 (92.5) 0.096
Oral antiglycaemic agents 228 (12.7) 36 (7.8) 192 (14.4) <0.0001
PPIs 746 (41.5) 206 (44.5) 540 (40.4) 0.125
ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; LBBB, left bundle branch block; LMWH, low-molecular-weight heparin; NSTEMI,
non-ST-segment elevation myocardial infarction; PPIs, proton-pump inhibitors; STEMI, ST-segment elevation myocardial infarction; UA,
unstable angina; UFH, unfractionated heparin.
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In the HR-UA/NSTEMI group, invasive strategy (cor-
onary angiography) was applied in about two-thirds of
the patients, while 79.5% of the patients in STEMI/new
LBBB group underwent coronary angiography. Elective
PCI during hospital stay was performed in 20.0% of all
patients. Among the patients who underwent PCI,
71.9% received drug-eluting stents, 22.6% received bare-
metal stents and 5.5% received both types of stents.
During the hospital stay, 10.0% of the patients under-
went CABG surgery.
Postdischarge adherence to antiplatelet therapy
Table 4 shows the compliance with guideline-recom-
mended antiplatelet treatment for patients with ACS at
discharge, and 1 month and 1 year after discharge. At
discharge, 77.5% of the patients with STEMI/new LBBB
received guideline-compliant antiplatelets, but this
amount gradually decreased and only about half of the
patients with STEMI/new LBBB had full adherence to
guideline-recommended antiplatelet treatment at 1 year.
In the HR-UA/NSTEMI group, 67.0% were discharged
with guideline-recommended antiplatelet regimens, but
only 28.3% of the patients were using antiplatelets in
compliance with the guideline for the entire 12 months
after discharge. Moreover, at discharge and 1 and
12 months after discharge, the patients who had under-
gone PCI or CABG during index hospitalisation were
more likely than patients scheduled for conservative
Table 3 In-hospital reperfusion and revascularisation strategies in the study patients
Characteristics Total (n=1799) STEMI/new LBBB (n=463) UA/NSTEMI (n=1336) p Value
Reperfusion strategies, n (%)
No reperfusion – 153 (33.6) – –
Primary CABG – 13 (2.9) – –
Thrombolytic therapy – 211 (46.3) – –
Symptom onset to thrombolytic – 269.0±477.3 – –
Door-to-needle time – 45.6±41.1 – –
Primary PCI – 79 (17.3) – –
Symptom onset to PCI – 256.8±186.6 – –
Door-to-balloon time – 82.8±112.5 – –
Revascularisation strategies, n (%)
Coronary angiography 1232 (68.5) 368 (79.5) 864 (64.7) <0.0001
PCI (excluding primary PCI) 360 (20.0) 133 (28.7) 227 (17.0) <0.0001
DES 258 (71.9) 94 (70.1) 164 (72.9) 0.764
BMS 81 (22.6) 33 (24.6) 48 (21.3)
Both 20 (5.5) 7 (5.2) 13 (5.8)
CABG surgery 180 (10.0) 34 (7.3) 146 (10.9) 0.049
All plus-minus values are mean±SD.
BMS, bare metal stent; CABG, coronary artery bypass grafting surgery; DES, drug-eluting stent; LBBB, left bundle branch block; NSTEMI,
non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial
infarction; UA, unstable angina.
Table 4 Adherence to postdischarge guideline-recommended antiplatelet therapy
At discharge
1 Month after
discharge
1 Year after
discharge Full adherence
Yes No Yes No Yes No Yes No
STEMI/new LBBB 359 (77.5) 104 (22.5) 322 (72.4) 123 (27.6) 207 (51.8) 193 (48.3) 197 (49.7) 199 (50.3)
Revascularisation* 210 (85.0) 37 (15.0) 193 (80.4) 47 (19.6) 141 (64.1) 79 (35.9) 139 (63.5) 80 (36.5)
Conservative
management
149 (69.0) 67 (31.0) 129 (62.9) 76 (37.1) 66 (36.7) 114 (63.3) 58 (32.8) 119 (67.2)
UA/NSTEMI 895 (67.0) 441 (33.0) 753 (58.6) 533 (41.4) 424 (37.9) 695 (62.1) 313 (28.3) 792 (71.7)
Revascularisation* 300 (77.7) 86 (22.3) 288 (76.6) 88 (23.4) 156 (46.0) 183 (54.0) 105 (31.3) 230 (68.7)
Conservative
management
595 (62.6) 355 (37.4) 465 (51.1) 445 (48.9) 268 (34.4) 512 (65.6) 208 (27.0) 562 (73.0)
Total 1254 (69.7) 545 (30.3) 1075 (62.1) 656 (37.9) 631 (41.5) 888 (58.5) 510 (34.0) 991 (66.0)
Revascularisation* 510 (80.6) 123 (80.6) 481 (78.1) 135 (21.9) 297 (53.1) 262 (46.9) 244 (44.0) 310 (56.0)
Conservative
management
744 (63.8) 422 (36.2) 594 (53.3) 521 (46.7) 334 (34.8) 626 (65.2) 266 (28.1) 681 (71.9)
* PCI or CABG during index hospitalisation.
CABG, coronary artery bypass grafting surgery; LBBB, left bundle branch block; NSTEMI, non-ST-segment elevation myocardial infarction;
PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina.
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management to receive antiplateletes according to the
ACC/AHA recommendations for antiplatelet treatment
in patients with ACS.
Postdischarge outcomes
Table 5 demonstrates the 1-year postdischarge outcomes
of the study patients. During the entire study period, 70
patients died (22 in the STEMI/new LBBB group and
48 in the HR-UA/NSTEMI group). Although 1-year
total postdischarge mortality did not show significant
difference between the two groups, the cardiovascular
mortality was higher in patients with STEMI/new LBBB
than in patients with HR-UA/NSTEMI, with statistically
borderline significance (5.2% vs 3.9%, respectively,
p=0.061). Moreover, patients with STEMI/new LBBB
were more likely to undergo PCI (15.9% vs 7.7%) or
CABG (9.0% vs 6.5%) after discharge. During the
12-months follow-up, MACCEs occurred in 15.0% of all
patients and the rate of the MACCE was similar in the
STEMI/new LBBB and HR-UA/NSTEMI groups. Of the
entire patient group, 1.4% experienced at least one
episode of bleeding during 1-year follow-up, of which
30.4% were major bleeds. Patients with STEMI/new
LBBB and HR-UA/NSTEMI were found to have similar
rates of bleeding, and of similar severity, during the
12 months after discharge.
Predictors of a 1-year postdischarge MACCE
Table 6 shows the independent predictors of MACCEs
during 1-year follow-up in the STEMI/new LBBB and
HR-UA/NSTEMI groups separately. In the patients with
STEMI/new LBBB, LVEF≤40% was associated with
increased risk of a MACCE at 1-year postdischarge (OR
1.69; 95% CI, 1.03 to 2.75, p=0.036). Typical ischaemic
chest pain at presentation was independently associated
with lower risk of a MACCE at 12 months after discharge
in patients with STEMI (OR 0.24; 95% CI, 0.09 to 0.62,
p=0.003). CABG during the index hospitalisation or
later during the first year after discharge was associated
with lower risk of a MACCE at 1 year but the statistical
significance was borderline (OR 0.27, p=0.087). Among
the patients with HR-UA/NSTEMI, (a positive history
of) DM, a high heart rate at presentation and history of
PCI were associated with significantly increased risk of a
MACCE at 12 months after discharge; revascularisation
during index hospitalisation was, rather, associated with
a lower MACCE risk (OR 0.356, 95% CI, 0.233 to 0.543,
p<0.0001).
DISCUSSION
The IPACE2 study is the first to evaluate the clinical
characteristics, and contemporary diagnostic and thera-
peutic strategies applied to patients with ACS in Iran. In
addition, this survey sheds light on the mid-term progno-
sis and its predictors in a wide spectrum of ‘real world’
Iranian patients with ACS.
In our study, almost one-fourth (25.7%) of patients
with ACS had STEMI, which is similar to proportions
reported from developed countries,14–16 and it is signifi-
cantly lower than the values reported from Gulf coun-
tries (45.6%), India (60%), and developing countries
in Latin America and Africa17–20 (table 7). This
outcome is likely to be the result of overall younger age
(56–57 vs 60.1 years, respectively) and also higher
male/female ratio of the patients with ACS in these
countries than in ours (3.73 vs 1.89, respectively).
Moreover, several factors in addition to the younger age
of the population in Arabian countries—including the
significantly higher prevalence of DM (39.5% vs 31.1%)
and current or past smoking (52.9% vs 39.7%)—in
their studied population, not as considerable in ours,
may be accountable for the observed difference.
However, with a mean age of 60.1 years, participants in
Table 5 One year postdischarge outcomes of the study patients
Characteristics Total (n=1640) STEMI/new LBBB (n=421) UA/NSTEMI (n=1219) p Value
Mortality 70 (4.3) 22 (5.2) 48 (3.9) 0.267
Cardiac 50 (71.4) 19 (86.4) 31 (64.6) 0.061
Non-cardiac 20 (28.6) 3 (13.6) 17 (35.4)
Acute coronary syndrome 156 (9.5) 36 (8.5) 120 (9.8) 0.427
Congestive heart failure 54 (3.3) 12 (2.8) 42 (3.4) 0.551
CABG 117 (7.1) 38 (9.0) 79 (6.5) 0.081
PCI 161 (9.8) 67 (15.9) 94 (7.7) <0.0001
Stroke/TIA 20 (1.2) 5 (1.2) 15 (1.2) 0.940
Bleeding 23 (1.4) 6 (1.4) 17 (1.4) 0.969
Severe 7 (30.4) 2 (33.3) 5 (29.4)
Moderate 4 (17.4) 1 (16.7) 3 (17.6)
Mild 12 (52.2) 3 (50.0) 9 (52.9)
MACCE* 246 (15.0) 63 (14.9) 183 (15.0) 0.996
*MACCE including stroke/TIA, acute coronary syndrome and mortality.
CABG, coronary artery bypass grafting surgery; LBBB, left bundle branch block; NSTEMI, non-ST-segment elevation myocardial infarction;
PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIA, transient ischaemic attack; UA, unstable
angina.
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our study were significantly younger than those in the
developed countries.1 14 16 17 21 22
The latest ACC/AHA guidelines for management of
patients with STEMI recommends ≤30 min for
door-to-needle time, ≤90 min for door-to-balloon time
and ≤120 min for total ischaemic time, as the goal of
reperfusion timing.4 Although our patients with STEMI
were reperfused within acceptable lengths of time with
respect to median door-to-needle time (mean:
45.6 min/median: 30 min) and door-to-balloon time
(mean: 82.8 min, median: 53 min), it took an average of
about 265 min (median: 160 min) for our patients with
STEMI to reach the emergency department, which is
higher than median times reported from developed
countries.1 16 21 The causes responsible for long delays
before hospital arrival of patients with STEMI in the
Iranian population should be elucidated in future
studies.
Similar to recent trends reported by other ACS regis-
tries,1 8 10 16 17 21 23–26 our study showed high compli-
ance with guideline-recommended medications in the
first 24 h of admission in Iranian patients with ACS,
which demonstrates the good knowledge, attitude and
practice of Iranian physicians with respect to the
guideline-recommended in-hospital management of
patients with ACS.
Despite the established beneficial effect of DAPT on
outcomes of ACS and current ACC/AHA recommenda-
tions regarding antiplatelet treatment in patients with
ACS,3 4 global experiences have shown underutilisation
of dual antiplatelet agents in patients with ACS, espe-
cially in those who were diagnosed as having acute MI
and those who did not undergo PCI.1 10 14 18 19
24 25 27 28 In our study, 91.8% of all patients, including
98.1% of the patients with STEMI/new LBBB and
89.7% of the patients with HR-UA/NSTEMI, received
clopidogrel during the hospitalisation for ACS, which is
significantly higher than previously reported values from
other registries.1 10 14 18 19 24 25 27 28 However, only
69.7% of our patients with ACS, including 77.5% of the
patients with STEMI/new LBBB and 67.0% of the
patients with HR-UA/NSTEMI, were prescribed DAPT at
discharge, and these values progressively declined over
time. In the IPACE2 study, only half of the patients in
the STEMI/new LBBB group and one-third of the
patients in the HR-UA/NSTEMI group who were dis-
charged with DAPT, completed the treatment for 1 year.
Given the weight of evidence supporting DAPT use
throughout the wide spectrum of ACS, there is a sub-
stantial opportunity to reinforce the appropriate use of
these medications in the management of the spectrum
of ACS to improve clinical outcome.
In this study, we observed that patients with STEMI/
new LBBB and HR-UA/NSTEMI had similar incidence
of all-cause mortality and MACCE during the year after
discharge. However, cardiovascular mortality was signifi-
cantly higher in patients with STEMI/new LBBB than in
patients with HR-UA/NSTEMI and, conversely, non-
cardiac mortality was higher among patients with
HR-UA/NSTEMI than among the STEMI/new LBBB
group. This finding is in agreement with Polonski et al,14
who observed an adjusted worse long-term prognosis in
patients with STEMI than that in patients with NSTEMI.
The reasons for higher mid-term non-cardiac mortality
in patients with HR-UA/NSTEMI might be: (1) older
age of patients with HR-UA/NSTEMI than those in the
STEMI/new LBBB group and (2) higher prevalence of
major comorbidities in the HR-UA/NSTEMI group,
such as DM, hypertension and hyperlipidaemia, which
are associated with worse prognosis and mortality.
In this study, we observed that presentation of STEMI
with a typical ischaemic chest pain was associated with a
decreased risk of a MACCE at 1-year postdischarge. This
finding supports and expands the findings by Canto
et al,29 which revealed that patients with MI without
typical chest pain were less quickly diagnosed and
treated, and had higher adjusted odds of hospital mor-
tality, regardless of whether they had ST-segment eleva-
tion. The authors observed that patients without typical
chest pain/discomfort were less likely to receive medica-
tions with established survival benefits and/or undergo
timely reperfusion.29 In this IPACE2 study, we observed
that DM significantly increased the risk of 1-year post-
discharge MACCE in patients with HR-UA/NSTEMI.
Table 6 Independent predictors of the major adverse cardiovascular events during 1-year postdischarge in patients with
STEMI/new LBBB and HR-UA/NSTEMI
Variable
STEMI/new LBBB UA/NSTEMI
OR (95% CI) p Value OR (95% CI) p Value
Ischaemic-type chest pain 0.24 (0.09 to 0.62) 0.003 – –
Heart rate (bpm) – – 1.01 (1.000 to 1.016) 0.048
Diabetes mellitus – – 2.23 (1.64 to 3.03) <0.0001
Hx of PCI before admission – – 1.61 (1.06 to 2.44) 0.025
Revascularisation* – – 0.356 (0.233 to 0.543) <0.0001
LVEF <40% 1.69 (1.03 to 2.75) 0.036 – –
*PCI or CABG during index hospitalisation.
CABG, coronary artery bypass grafting surgery; HR-UA, high-risk unstable angina; Hx, history; LBBB, left bundle branch block; LVEF, left
ventricular ejection fraction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI,
ST-segment elevation myocardial infarction.
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Table 7 Comparison of baseline characteristics, management and outcomes of acute coronary syndrome patients in developed and developing countries
NRMI
Expanded
GRACE EHS 2 PL-ACS
Portuguese
Registry of
ACS PACIFIC CREATE SPACE ACCESS
GULF-
RACE2 IPACE2
Sampling Period 1990–2006 2001–2007 2004 2003–2006 2002–2008 2008–2009 2002–2005 2005–2007 2007–2008 2008–2009 2011–2012
Source of data USA Multinational Europe and
mediterranean
basin
Poland Portugal Japan India Saudi
Arabia
Developing
countries
Gulf
countries
Iran
Patients, n 2 515 106 31 982 6385 100 193 22 482 3597 31 982 5055 12 068 7930 1799
Mean age, years 65 65 64 65 66 67 57 58 59 56 60
Male, % 58 NA 70 60 70 77 76 77 73 79 65
Current smoking, % 24 NA 37 27 24 NS 28 33 40 36 29
DM, % 29 26 24 23 27 35 30 58 24 39 31
STEMI, % 47 30 47 31 45 59 61 41.5 46 46 26
UA/NSTEMI, % 53 70 53 69 55 41 39 58.5 54 54 74
Symptom onset to
hospital arrival time,
(min)*
96 133 145 260 177 NA 300 150 240 176 160
Door-to-needle
time, (min)*
29 32 37 25 60 NA 50 52 NA 39 30
Door-to-balloon
time, (min)*
79 110 70 50 96 NA NA NA NA 87 53
Thrombolytic
therapy, %
28 33 41 9.3 44 NA 58.5 69.1 39 66 46
Primary PCI, % 43 16 58 54 19 63 8 17.5 22 22.3 17
Coronary
angiography†, %
78 70 66 39 61 96 23 67 58 32 68
30-day mortality, % NA NA 6.4/3.4 NA NA NA 8.6/3.8 NA 5/2.4 9.9/5 2.5/1.0
1-year mortality, % NA NA 7.5 NA NA 3/2.2 NA NA 8.4/6.3 11.5/7.7 5.2/3.9
*Times in patients with STEMI.
†During index hospitalisation.
CREATE, treatment and outcomes of acute coronary syndromes in India; DM, diabetes mellitus; EHS2, European heart survey II; GRACE, global registry of acute coronary events;
GULF-RACE2, gulf registry of acute coronary events-phase 2; IPACE2, Iranian Project for Assessment of Coronary Events 2; NA, not available; NRMI, national registry of myocardial infarction;
NS, not significant; PACIFIC, prevention of atherothrombotic incidents following ischemic coronary attack; PCI, percutaneous coronary intervention; PL-ACS, Polish Registry of Acute Coronary
Syndromes; SPACE, Saudi project for assessment of coronary events; STEMI, ST-segment elevation myocardial infarction; UA/NSTEMI, unstable angina/non-ST-segment elevation myocardial
infarction.
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Our finding supports and expands the study by Chong
et al,30 which observed that DM increases the risk of a
MACCE at 1 and 6 months after discharge in patients
with UA/NSTEMI. Park et al31 also observed that DM is
a predictor of early and late cardiac death in patients
with NSTEMI (and not STEMI). This suggests that,
among the traditional risk factors, presence of diabetes
may be the most predictive factor for adverse clinical
events after discharge in patients with HR-UA/NSTEMI.
The merits of our study are that it is the first and only
study on management and outcomes of patients with
ACS in Iran. However, our study had several limitations.
First, although the study was multicentred, with 20 hospi-
tals participating, it was not a population-based registry
and selection bias could have occurred. Second, there is
an inherent selection bias because of the observational
nature of the study design and the possibility of import-
ant unmeasured covariables having been missed. Finally,
although we compared our data with other international
ACS registries, caution has to be taken about making
absolute inferences, mainly because of the patient age
and timing differences between these studies and ours.
In conclusion, the IPACE2 study showed that compos-
ition of Iranian patients with ACS regarding the type of
ACS is similar to that in developed European countries
and is unlike that in developing countries of the Middle
East and Africa. We found that our patients with ACS
are treated with high levels of adherence to
guideline-recommended in-hospital medications, but
there was a substantial underuse of DAPT at discharge,
and it also progressively declined over time after dis-
charge. Moreover, Iranian patients with STEMI delayed
a long time before presenting to the hospital, but
in-hospital reperfusions were quite timely.
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